Kornimate/medical-research-clean huggingface dataset:
a study of two-weekly intravenous mircera for the treatment of dialysis patients with chronic renal anemia not receiving esa therapy.

Conditions: Anemia

Summary: this single arm study will evaluate the hemoglobin (hb) increasing effect, safety and tolerability of two-weekly intravenous administration of mircera in dialysis patients with chronic renal anemia not currently treated with esas. patients will receive intravenous mircera 0.6 micrograms/kg every 2 weeks for 16 weeks with follow up 2 weeks after the last treatment visit. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * male or female patients, \>=18 years of age; * chronic renal anemia (hb concentration 8.0g/dl - 10.0g/dl); * no prior erythropoietin stimulating agent (esa) therapy. exclusion criteria: * blood transfusion within the previous 4 weeks; * poorly controlled hypertension; * significant acute or chronic bleeding; * active malignant disease; * congestive heart failure (nyha class iv).
rct iron supplementation and malaria chemoprophylaxis for prevention of severe anemia and malaria in tanzanian infants

Conditions: Malaria; Anemia

Summary: the purpose of this trial is to evaluate the efficacy of weekly iron supplementation and the efficacy of malaria chemoprophylaxis from 2 to 12 months of age in infants living in an area of intense and perennial malaria transmission

411 tanzanian infants were randomly assigned to receive weekly malaria prophylaxis with deltaprim™ (3.125 mg pyrimethamine plus 25 mg dapsone) or placebo from ages 2-12 months. children were followed-up until age 4 years. uncomplicated febrile malaria, severe malaria and anaemia morbidity were assessed through hospital-based passive surveillance.

Eligibility criteria:
inclusion criteria: * born in san francis designated district hospital of ifakara exclusion criteria: * obvious severe congenital malformation such as: spina bifida, hydrocephalus or anencepahlus * twins * birth weight \< 1,5 kg * clinical signs of cerebral asphyxia * clinical signs of neonatal or congenital infection * mother unreliable (deaf, mentally handicapped)

Keywords: plasmodium falciparum antimlarial chemoprophylaxis iron supplementation tanzania
fluticasone propionate-salmeterol combination adherence in patients with chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the specific aim of this study is to describe 1 year advair dispensing rates for patients with copd, and to measure the association between advair adherence and healthcare utilization (e.g. emergency room visits and inpatient admissions, etc.). to compare the risk of a copd exacerbation (moderate or severe) during a 3-month follow-up period between patients thqat are adherent versus those that are not.


Eligibility criteria:
inclusion criteria * at least one pharmacy claim for advair (any strength; diskus or mdi) during the index year (july 1, 2005 through june 30, 2006). * continuous medical and pharmacy eligibility for the 12 month pre-index year and the 12 month index year (referred to as the 24 month observation period), and the 3 month post-index period (referred to as the outcome period). * at least one medical claim with a diagnosis (either primary or secondary) of copd (icd-9 code 490.xx, 491.xx, 492.xx, and 496), and at least 1 pharmacy claim for an anticholinergic medication, both occurring during the12 month pre-index period. * at least 40 years old at index date. exclusion criteria * any medical claim (ever) with a primary or secondary diagnosis of cystic fibrosis (icd-9 code 277.0x).
adipose tissue and polycystic ovary syndrome (pcos)(eiffel)

Conditions: Polycystic Ovary Syndrome; Metabolic Diseases; Overweight

Summary: the purpose of this study is to collect data to help understand why some women develop polycystic ovary syndrome (pcos) associated with decreased lower-body fat.

epigenetics may represent a new regulator mechanism explaining gluteal vs. abdominal fat differences.

Eligibility criteria:
inclusion criteria: * female * age \> 20 and \< 40 * weight stable (change of less than 3 kg in the last 8 weeks) * bmi \ 27 kg/m2 supplemental inclusion criteria for pcos women: * nih criteria - confirmed by subjects' medical records. exclusion criteria: * male * women who are pregnant or lactating (breast feeding) * post-menopausal women * women with hysterectomy * diagnosed with diabetes, or have a fasting blood sugar \> 126 mg/dl. * untreated or symptomatic thyroid disease. * impaired kidney or liver function, as evidenced by your blood work * hypertension/ high blood pressure or are taking blood pressure medications * use of oral contraceptives or hormone replacement therapy. * history of drug or alcohol abuse (\> 3 drinks per day) in the last 5 years, or psychiatric disease prohibiting adherence to study protocol. * history of cancer within the last 5 years. * history of organ transplant. * history of hiv, active hepatitis b or c, or tuberculosis. * history of heart attack/ myocardial infarction. * presence of clinically significant abnormalities on ekg. * current smokers (smoking within the past 3 months) * use of any medications known to influence glucose, fat and/or energy metabolism within the last 3 months (e.g., growth hormone therapy, glucocorticoids \[steroids\], etc.). metformin for women with pcos is allowed.

Keywords: abdominal adipose gluteal adipose polycystic ovary syndrome obesity women
follow-up evaluation using ct scans in patients who have been treated for metastatic testicular cancer

Conditions: Testicular Germ Cell Tumor

Summary: rationale: learning about long-term effects in patients with testicular cancer may help doctors plan better treatment and follow-up care. purpose: this clinical trial is using ct scans to follow patients who have been treated for metastatic testicular cancer.

objectives: * to assess the frequency of relapse or recurrent abnormalities detected by ct scan in patients on long-term follow-up for metastatic nonseminomatous germ cell tumour (nsgct). * to assess the utility of ct scan-assessment in these patients. * to assess the prognostic factors predictive of late relapse in nsgct. outline: this is a multicenter study. patients are screened by ct scan of the chest, abdomen, and pelvis for detectable abnormalities or indications of late relapse. scans are classified as positive or negative, according to standard ct criteria, by a radiologist with expertise in testicular cancer imaging. patients with negative scans are followed yearly by clinical examination and tumor marker assessment, and every 5 years by ct imaging. additional follow-up is performed at the discretion of the attending physician. patients with positive scans undergo confirmation of relapse, whenever possible, by surgical excision or biopsy and treatment is initiated according to best clinical practice. if the follow-up scan is equivocal, patients are advised to have a follow-up scan of the affected region in 6 months.

Eligibility criteria:
disease characteristics: * diagnosis of metastatic nonseminomatous germ cell tumor (nsgct) at risk of developing late relapse of residual abnormality * royal marsden hospital stage ii-iv disease * treatment for nsgct completed within the past 5 to10 years * no evidence of disease after completion of chemotherapy, as demonstrated by negative ct scans within the past 3 years patient characteristics: * willing to attend follow-up for five years * no contraindication to ct imaging prior concurrent therapy: * see disease characteristics

Keywords: stage ii malignant testicular germ cell tumor stage iii malignant testicular germ cell tumor
effects of carrageenan-elimination diet on ulcerative colitis disease activity

Conditions: Ulcerative Colitis

Summary: the study hypothesis is that withdrawal of carrageenan will lead to a longer, relapse free interval in patients with ulcerative colitis.

this study will evaluate the interval to relapse in patients with ulcerative colitis. the patients will be adults, who have been in remission for at least one month. they will have previously required corticosteroids to induce remission. subjects will be instructed in a no-carrageenan diet and required to follow this diet for the duration of their participation in the clinical study. they will be randomized to receive either placebo capsules or capsules containing carrageenan 100 mg. in this way, the study will be a double blind study of no-carrageenan vs. carrageenan. main study outcome is the interval to relapse. since ulcerative colitis is associated with relapses, relapse is anticipated. other outcome measures will include scores on questionnaires, including the sscai and the sidbq, and laboratory measurements of inflammation. subjects will participate for one year or until relapse, with study visits every three months and telephone contacts every two weeks. after three months, participants will increase to two capsules daily, of either placebo or carrageenan.

Eligibility criteria:
inclusion criteria: * ulcerative colitis * adult * in remission * required corticosteroids to induce remission * able to make food choices and follow diet exclusion criteria: * not able to make food choices

Keywords: relapse carrageenan inflammation
influence of varenicline on the antiplatelet action of clopidogrel

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to investigate the effects of steady-state varenicline on the antiplatelet action of clopidogrel in patients with coronary artery disease.

smoking is a major risk factor for cardiovascular disease (cvd). compared with nonsmokers, smokers are approximately twice as likely to develop cvd, and three times more likely to die from it. this increased risk is due to the deleterious effects of smoking on endothelial function and blood coagulation, and the development of coronary atherosclerotic plaques. a research showed that continued smoking after successful percutaneous coronary intervention(pci) is associated with an increased risk of restenosis. however, smoking cessation can make a 36% reduction in crude relative risk (rr) of mortality for patients with cvd. hence current management guidelines now advocate smoking cessation, in addition to controlling hypertension and dyslipidemia, as part of an overall cardiovascular risk reduction strategy. varenicline is a novel selective nicotinic acetylcholine receptor partial agonist that has been approved in over 70 countries worldwide as an aid to smoking cessation. clopidogrel is widely used by patients with coronary artery disease undergoing pci. the relationship between smoking and cardiovascular disease increases the prospect of patients receiving smoking cessation therapy and clopidogrel concomitantly in clinical practice. plasma protein binding of varenicline is low(≤20%) and independent of age or renal function. the major route of clearance for varenicline is renal excretion. clopidogrel, a prodrug, is metabolized by 2 consecutive cytochrome p450-dependent steps to its active metabolite, which binds irreversibly to the platelet p2y12 receptor. the likelihood of a clinically relevant drug-drug interaction between varenicline and clopidogrel was considered to be low; nevertheless, the possibility of an interaction between these 2 drugs is lack of clinical evidences. hence, our hypothesis is that varenicline may have no influence on the antiplatelet action of clopidogrel.

Eligibility criteria:
inclusion criteria: * patients with coronary artery disease(cad) undergoing pci in hospital * smoke 10 or more cigarettes per day * fewer than 3 months of smoking abstinence in the past year * motivation to stop smoking exclusion criteria: * history of previous treatment with clopidogrel or varenicline * thrombocytopenia(\<150,000 platelets/ml) * bleeding disorder * liver disease * gastrointestinal ulcer * pregnancy * cancer * clinically significant allergic reactions * mental disorders * drug or alcohol abuse

Keywords: coronary artery disease varenicline clopidogrel
validation of apnealink air home sleep testing in the diagnosis of obstructive sleep apnea in adolescent children

Conditions: Sleep Apnea, Obstructive

Summary: the feasibility and the validity of the apnealink air home sleep testing (hst) device will be tested in adolescent children. the apnealink air hst device is cleared for the diagnosis of obstructive sleep apnea (osa) in adults..

obstructive sleep apnea is highly prevalent in children affecting 2-3% of children and up to 10% of obese children. the reported prevalence is likely underestimated due to the lack of available laboratory polysomnography (psg) testing for children. the high prevalence of osa coupled with an increase in obesity, a major risk factor of osa in children, has resulted in a significant strain for in laboratory psg including children in the greater san diego county. currently, hst in children is restricted based on the limited availability of hst devices on children that have attained clearance by the us food and drug administration (fda). in this study, the feasibility and the validity of the apnealink air hst device will be tested in children 12 years old and over. the apnealink air hst device is cleared for the diagnosis of osa in adults and is frequently used amongst adult sleep medicine physicians. adolescent children will be recruited whose clinically indicated in laboratory psg will be performed at rady children's hospital. concurrent to their in-laboratory psg, they will have their sleep assessed using the apnealink air device. ten children will repeat the apnealink air hst at home following their sleep study within one week, and the remaining ten children will have their apnealink air hst performed within one week prior to their in laboratory clinically indicated psg.

Eligibility criteria:
inclusion criteria: * patients presenting with symptoms of osa needing a sleep study * patients between the ages of 12 and 17 years, inclusive exclusion criteria: * patients less than 12 years old * patients 18 years old or older * children with syndromes or congenital disease including down syndrome, prader-willi syndrome, children with craniofacial disorders, and finally children with congenital heart disease or pulmonary hypertension
pq bypass guide wire delivery system for femoropopliteal bypass

Conditions: Peripheral Arterial Disease

Summary: to assess the safety of performing a percutaneous fem-pop bypass using the pq bypass guidewire delivery system and commercially available stent grafts.

multi-center, single-arm first-in-man study utilizing the pq bypass guide wire delivery system to access, deliver guidewires and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.

Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent * age 18 or older * rutherford classification of 3-5 * lesions ≥10cm in length considered to be: * chronic total occlusion (100% stenosis) * diffuse stenosis (\>50% stenosis) with moderate to heavy calcification * in-stent restenosis (\>50% stenosis) * proximal and distal target vessels are 4.8 - 7.5 mm in diameter * orifice and proximal 1cm of sfa is patent * patent popliteal artery 3cm proximal to tibial plateau * at least 1 patent tibial artery to the foot * patent femoral vein exclusion criteria: * history of deep vein thrombosis * has a known sensitivity or allergy to contrast materials that cannot be adequately pre-treated * has a known sensitivity or allergy to aspirin, heparin or anti-platelet medications * documented in-sensitivity to anti-platelet medication * has a known or previous coagulopathy * pregnant or lactating * untreated flow-limiting aortoiliac occlusive disease * has renal failure (gfr \< 30ml/min) * major distal amputation (above the transmetatarsal) in the study or non-study limb * patient has had a procedure on the target limb within 30 days * previous bypass surgery on the target limb * bypass length required is greater than 35cm
safety and tolerability of intravenous doses of activated recombinant human factor vii in healthy volunteers

Conditions: Congenital Bleeding Disorder; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to investigate the pharmacokinetics of three different single doses activated recombinant human factor vii in caucasian and japanese healthy subjects.


Eligibility criteria:
inclusion criteria: * caucasian or japanese * healthy as defined by medical history, physical and biological examinations exclusion criteria: * history of allergy or hypersensitivity reaction to any medication * history or presence of any organic disorder likely to modify absorption, distribution or elimination of the medication * alcohol or substance abuse disorder * subject in his exclusion period in the healthy volunteers national register of the french ministry of health
impact of the information leaflet on the anesthesia knowledge and anxiety levels of children and parents

Conditions: Anxiety; Preoperative Anxiety; Pediatric Anesthesia

Summary: the study includes applying a questionnaire to each child and their parents who applied to the anesthesia outpatient clinic for the gastroenterological endoscopic procedure. children and parents will be divided into two groups, those who received and those who did not receive information leaflet. with the questionnaire both groups will be compared in terms of knowledge level and anxiety level.

all children under the age of 18, who meet the inclusion criteria, applied to the outpatient clinic for the preoperative anesthesia evaluation will be included in the study. during the preoperative anesthesia examination, pediatric patients and their parents will be informed about the study, their consent will be obtained, and their demographic data will be recorded. information leaflets will be given to the one group in that both the child and their parents will read it before the endoscopic procedure. children will handed leaflet appropriate for their age. the other group will not receive information leaflets. routine information about anesthesia will be given to both groups. demographic data, m-ypas(the modified yale preoperative anxiety scale), apais(amsterdam preoperative anxiety and information scale) will be evaluated for both groups before anesthesia induction. the anesthesiologist evaluate anxiety of children, will not know whether the patients received an information leaflets. parents will be asked to fill out the questionnaire in the waiting room. anxiety scores will be evaluated by apais. the source of their knowledge about anesthesia, how anesthesia applications are made during endoscopy procedures and what their fears about anesthesia are will be evaluated.

Eligibility criteria:
inclusion criteria: * all children under the age of 18 and their parents who applied to the anesthesia outpatient clinic before the gastroenterological endoscopic procedure * knowing turkish language * agreeing to participate in the research voluntarily * parent and child not having a diagnosed neuropsychiatric disease * literacy of the child and parent * not having verbal communication barrier exclusion criteria: * refusing to participate in the research * not knowing turkish language * having a verbal communication barrier * parent and child have a diagnosed neuropsychiatric disease * illiteracy of the child or parent

Keywords: anxiety; anesthesia; preoperative care; child
a study of postoperative adjuvant chemotherapy for upper urinary urothelial carcinoma with lymphovascular invasion

Conditions: Chemotherapy Effect

Summary: this project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with ptanyn0m0 upper urinary urothelial carcinoma with lymphatic vascular invasion (lvi) through a prospective case-control study.

this project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with ptanyn0m0 upper urinary urothelial carcinoma with lymphatic vascular invasion (lvi) through a prospective case-control study. therapeutic value of adjuvant chemotherapy for lvi(+) patients with pt1n0m0, pt2n0m0, and pt3-4n0m0 upper urinary urothelial carcinoma, respectively.

Eligibility criteria:
inclusion criteria: 1. aged 20-85 years; 2. ecog score 0-1 points; 3. patients with utuc, undergoing radical nephrectomy, pathological staging for ptanyn0m0; 4. patients voluntarily signed informed consent. exclusion criteria: 1. obvious cardiopulmonary dysfunction, serious diabetes and other chronic diseases; 2. obvious chemotherapy contraindications; 3. patients have a history of other organ malignancies; 4. combined with tumors of other sites.
effect of neurodynamic mobilization on median nerve conduction velocity in carpal tunnel syndrome

Conditions: Median Nerve Entrapment; Carpal Tunnel Syndrome

Summary: the purpose of this study is to examine: 1. the effect of neurodynamic mobilization on the sensory and motor median nerve conduction velocity in carpal tunnel syndrome. 2. the effect of neurodynamic mobilization on the wrist pain in carpal tunnel syndrome. 3. the effect of neurodynamic mobilization on the hand function in carpal tunnel syndrome.

the findings of this study will provide physiotherapists with information to know if neurodynamic mobilization techniques is effective on median nerve conduction velocity in carpal tunnel syndrome also this will improve our body of knowledge about the best modalities for treating carpal tunnel syndrome. the finding of this study may help carpal tunnel syndrome patients to avoid the exposing to complications as a result of compression of median nerve in carpal tunnel syndrome.

Eligibility criteria:
inclusion criteria: * forty carpal tunnel syndrome patients. * all participants referred from a physician. * their ages range from 20-50 years old. * both genders will participate in the study. * their bmi ranges between 18.5-24.9kg/m2. * all participants have carpal tunnel syndrome at least in one hand. * all participants suffering from mild to moderate carpal tunnel syndrome. exclusion criteria: * previous or current disease or trauma that might affect one or both upper limbs. * metabolic diseases that might associated with entrapment neuropathy such as diabetes mellitus, thyroid diseases, and autoimmune diseases. * pregnant women. * participants with congenital hand deformities. * history of hand surgery. * sever cases of carpal tunnel syndrome that suffering from weakness of hand grip and atrophy of thenar muscle.